Upon joining the study, the patient must have been diagnosed with multiple myeloma and have completed 12 cycles of treatment with daratumumab, lenalidomide, and dexamethasone (Dara-Rd).

The patient must be at least 18 years old and capable of providing informed consent.

The patient will be randomly assigned to one of two groups: continuous therapy or discontinuation of therapy.

In the continuous therapy group, the patient will continue receiving Dara-Rd until the disease progresses.

For those in the continuous therapy group, lenalidomide is taken orally, with a reduced dose allowed but not less than 5 mg per day.

Daratumumab is administered via subcutaneous injection.

Dexamethasone is taken orally, with previous dose reductions allowed.

The patient’s health and response to treatment will be regularly monitored to assess event-free survival and progression-free survival.

The study will evaluate the time to response and maximal response after restarting therapy in the discontinuation group.

For patients in the discontinuation group, therapy will be paused until biochemical progression is observed.

Upon progression, therapy with Dara-Rd will resume until further disease progression.

The study is estimated to conclude by September 8, 2030.

The primary endpoints include event-free survival and progression-free survival, while secondary endpoints focus on quality of life, treatment-free intervals, and overall survival.